<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321373</url>
  </required_header>
  <id_info>
    <org_study_id>107022</org_study_id>
    <secondary_id>107191</secondary_id>
    <nct_id>NCT00321373</nct_id>
  </id_info>
  <brief_title>Study to Evaluate an Influenza Vaccine Candidate</brief_title>
  <official_title>A Study to Demonstrate the Non-Inferiority of Influenza Vaccine Candidate, Compared With Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years Old and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immune response and safety of influenza vaccine
      candidate with or without adjuvant compared to Fluarix™ administered intramuscularly in
      elderly aged 60 years old and above.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized into 3 groups and will be followed for 6 months with 4 scheduled
      contacts per subjects. The immune response will be evaluated at days 0, 21 and 180 after
      vaccination. The safety evaluation will involve follow-up of solicited local and general
      signs and symptoms, unsolicited adverse events and serious adverse events.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Virus</measure>
    <time_frame>At Days 0 and 21 post-vaccination</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia, A/New York and B/Malaysia. The reference seropositivity cut-off value was ≥ 1:10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Virus</measure>
    <time_frame>At Day 180 post-vaccination.</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia, A/New York and B/Malaysia. The reference seropositivity cut-off value was ≥ 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling spreading beyond 50 millimeters (mm) of injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow up period after vaccination</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)], headache, muscle aches, shivering. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (Day 0 to Day 180)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Any = occurrence of any SAE regardless of intensity grade or relation to vaccination. Related = SAE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the 30-day (Days 0-29) follow-up period after vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1220</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK1247446A-AS03 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1247446A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Candidate Influenza Vaccine GSK1247446A - 2 different formulations</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>GSK1247446A Group</arm_group_label>
    <arm_group_label>GSK1247446A-AS03 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluarixTM</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A male or female age 60 years or older at the time of the vaccination.

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by clinical
             examination before entering into the study.

        Exclusion criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding the administration of the study vaccine, or planned use during the study
             period.

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality, as determined by physical examination or laboratory screening tests.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within three months prior to the first vaccine dose.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study. Planned administration
             of a vaccine not foreseen by the study protocol up to 30 days after vaccination.

          -  History of hypersensivity to a previous dose of influenza vaccine.

          -  Previous vaccination against influenza within the 9 months prior to enrollment.

          -  History of confirmed influenza infection within the last 12 months.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine(s)

          -  Acute disease at the time of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kotka</city>
        <zip>48100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goudi / Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haidari</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marousi</city>
        <zip>151 26</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nikaia Piraeus</city>
        <zip>184 54</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orestiada</city>
        <zip>682 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2006</study_first_submitted>
  <study_first_submitted_qc>May 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <results_first_submitted>March 14, 2013</results_first_submitted>
  <results_first_submitted_qc>March 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2013</results_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>107022</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107022</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107022</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107022</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107022</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1220 subjects were enrolled in the study. Study duration was of approximately 6 months (180 days) for all subjects.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK1247446A-AS03 Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK1247446A Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="406"/>
                <participants group_id="P3" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="405"/>
                <participants group_id="P2" count="406"/>
                <participants group_id="P3" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1247446A-AS03 Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK1247446A Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="407"/>
            <count group_id="B2" value="406"/>
            <count group_id="B3" value="407"/>
            <count group_id="B4" value="1220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="5.12"/>
                    <measurement group_id="B2" value="64.1" spread="4.95"/>
                    <measurement group_id="B3" value="64.2" spread="5.38"/>
                    <measurement group_id="B4" value="64.1" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="208"/>
                    <measurement group_id="B4" value="622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="199"/>
                    <measurement group_id="B4" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Virus</title>
        <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia, A/New York and B/Malaysia. The reference seropositivity cut-off value was ≥ 1:10.</description>
        <time_frame>At Days 0 and 21 post-vaccination</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity at Day 21 including subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A-AS03 Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Virus</title>
          <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia, A/New York and B/Malaysia. The reference seropositivity cut-off value was ≥ 1:10.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity at Day 21 including subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination at this time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 0 [N=395,393,389]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="12.3" upper_limit="14.8"/>
                    <measurement group_id="O2" value="13.9" lower_limit="12.6" upper_limit="15.3"/>
                    <measurement group_id="O3" value="14.2" lower_limit="13.0" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 0 [N=395,393,389]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="9.9" upper_limit="11.8"/>
                    <measurement group_id="O2" value="11.9" lower_limit="10.7" upper_limit="13.1"/>
                    <measurement group_id="O3" value="11.5" lower_limit="10.5" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 0 [N=395,393,389]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="16.0" upper_limit="19.7"/>
                    <measurement group_id="O2" value="16.0" lower_limit="14.4" upper_limit="17.8"/>
                    <measurement group_id="O3" value="15.6" lower_limit="14.0" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 21 [N=395,393,389]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.0" lower_limit="148.5" upper_limit="190.1"/>
                    <measurement group_id="O2" value="97.7" lower_limit="85.7" upper_limit="111.3"/>
                    <measurement group_id="O3" value="202.4" lower_limit="177.4" upper_limit="230.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 21 [N=395,393,389]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.8" lower_limit="159.3" upper_limit="202.9"/>
                    <measurement group_id="O2" value="70.4" lower_limit="61.3" upper_limit="80.7"/>
                    <measurement group_id="O3" value="104.3" lower_limit="91.5" upper_limit="118.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 21 [N=394,390,389]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341.2" lower_limit="305.7" upper_limit="380.9"/>
                    <measurement group_id="O2" value="175.4" lower_limit="154.1" upper_limit="199.5"/>
                    <measurement group_id="O3" value="292.0" lower_limit="257.1" upper_limit="331.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Virus</title>
        <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia, A/New York and B/Malaysia. The reference seropositivity cut-off value was ≥ 1:10.</description>
        <time_frame>At Day 180 post-vaccination.</time_frame>
        <population>The analysis was based on the ATP cohort for immunogenicity at Day 180 including subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A-AS03 Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Virus</title>
          <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia, A/New York and B/Malaysia. The reference seropositivity cut-off value was ≥ 1:10.</description>
          <population>The analysis was based on the ATP cohort for immunogenicity at Day 180 including subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination at this time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="383"/>
                <count group_id="O3" value="380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia at Day180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="57.6" upper_limit="71.8"/>
                    <measurement group_id="O2" value="54.3" lower_limit="48.3" upper_limit="61.0"/>
                    <measurement group_id="O3" value="84.4" lower_limit="74.8" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York at Day180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="50.9" upper_limit="63.5"/>
                    <measurement group_id="O2" value="35.8" lower_limit="31.7" upper_limit="40.3"/>
                    <measurement group_id="O3" value="42.4" lower_limit="37.7" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia at Day180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="79.0" upper_limit="99.3"/>
                    <measurement group_id="O2" value="65.2" lower_limit="58.0" upper_limit="73.3"/>
                    <measurement group_id="O3" value="90.9" lower_limit="80.7" upper_limit="102.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling spreading beyond 50 millimeters (mm) of injection site.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort that included all vaccinated subjects with the symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A-AS03 Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
          <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling spreading beyond 50 millimeters (mm) of injection site.</description>
          <population>The analysis was based on the Total Vaccinated Cohort that included all vaccinated subjects with the symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="404"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis &gt; 50mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness &gt; 50mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling &gt; 50mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)], headache, muscle aches, shivering. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) follow up period after vaccination</time_frame>
        <population>The analysis was based on the Total vaccinated Cohort which included all vaccinated subjects with the symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A-AS03 Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)], headache, muscle aches, shivering. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was based on the Total vaccinated Cohort which included all vaccinated subjects with the symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="404"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (oral) ≥37.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (oral) ≥39.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Any = occurrence of any SAE regardless of intensity grade or relation to vaccination. Related = SAE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the entire study period (Day 0 to Day 180)</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A-AS03 Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Any = occurrence of any SAE regardless of intensity grade or relation to vaccination. Related = SAE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 30-day (Days 0-29) follow-up period after vaccination</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A-AS03 Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was based on the Total Vaccinated Cohort which included all vaccinated subjects.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were collected during the entire study (Days 0-180). AEs were collected during the 30-day (Days 0-29) post-vaccination period. Solicited local/general symptoms were collected during the 7-day (Days 0-6) post-vaccination period.</time_frame>
      <desc>Non-serious AEs included solicited symptoms that were assessed on a subset of the Total Vaccinated Cohort, comprised of subjects who had symptom sheets completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK1247446A-AS03 Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK1247446A Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Uterine neoplasm</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Brain stem thrombosis</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>SAE reported from Day 0 to Day 30.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <description>SAE reported from Day 30 to Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="246" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="246" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

